Geneuin-Tech
Genuinely Giving Life is a global biotech company established to lead the future value of the Korean biotech industry through five unique recombinant virus technologies. The company aims to develop innovative biopharmaceuticals, including gene therapies, cell therapies, and vaccines, and to contribute to the treatment of rare diseases and other medical conditions. It is committed to advancing the biotech industry and providing new pathways for treatment and healthcare.
Industries
Nr. of Employees
small (1-50)
Geneuin-Tech
Gyeongsangnam-do, Gimhae-si, Inje-ro 197, Inje University Pharmacy Building 404
Patents
Humanized DR4 antibody gene having apoptosis-inducing activity and dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent using same
US-11603409-B2
View Details
Humanized DR4 antibody gene having apoptosis-inducing activity and dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent using same
US-11603409-B2
View DetailsProducts
Adenoviral intranasal vaccine platform
A live/replicating adenoviral vaccine platform optimized for intranasal (mucosal) delivery with preclinical evidence of mucosal antibody induction; positioned for respiratory pathogen targets and adaptable to multivalent vaccine designs.
AAV-based gene therapy programs for ocular and CNS indications
AAV vector programs targeting hereditary retinal diseases and CNS disorders with preclinical transgenic-model data showing restoration of retinal structure and targeted gene delivery strategies; collaborations with clinical ophthalmology investigators are referenced.
Dual-mechanism CAR-T constructs for solid tumors
CAR-T constructs designed to combine cytotoxic activity with induction of apoptotic pathways; preclinical studies report tumor reduction and improved survival with safety assessments.
RCA-minimizing adenovirus production cell line
Production cell line technologies intended to prevent generation of replication-competent adenovirus during manufacturing, aimed at improving production safety and enabling scale-up.
Adenoviral intranasal vaccine platform
A live/replicating adenoviral vaccine platform optimized for intranasal (mucosal) delivery with preclinical evidence of mucosal antibody induction; positioned for respiratory pathogen targets and adaptable to multivalent vaccine designs.
AAV-based gene therapy programs for ocular and CNS indications
AAV vector programs targeting hereditary retinal diseases and CNS disorders with preclinical transgenic-model data showing restoration of retinal structure and targeted gene delivery strategies; collaborations with clinical ophthalmology investigators are referenced.
Dual-mechanism CAR-T constructs for solid tumors
CAR-T constructs designed to combine cytotoxic activity with induction of apoptotic pathways; preclinical studies report tumor reduction and improved survival with safety assessments.
RCA-minimizing adenovirus production cell line
Production cell line technologies intended to prevent generation of replication-competent adenovirus during manufacturing, aimed at improving production safety and enabling scale-up.
Services
Custom production of recombinant viral vectors for research and preclinical use, including cloning, packaging, purification, concentration and titer measurement by real-time PCR (TaqMan). Public service specifications list typical target titers and base-case volumes for adenovirus, AAV, HSV, lentivirus and retrovirus. Order and consent templates and an online submission process are provided for customers.
Custom production of recombinant viral vectors for research and preclinical use, including cloning, packaging, purification, concentration and titer measurement by real-time PCR (TaqMan). Public service specifications list typical target titers and base-case volumes for adenovirus, AAV, HSV, lentivirus and retrovirus. Order and consent templates and an online submission process are provided for customers.
Expertise Areas
- Viral vector engineering and manufacturing
- Gene therapy development using AAV and other vectors
- Viral vaccine platform development including mucosal delivery
- CAR-T cell therapy design and preclinical development
Key Technologies
- Adenoviral vector systems
- AAV (adeno-associated virus) vectors
- Lentiviral and retroviral vector production
- Herpes simplex virus (HSV)-based vectors
News & Updates
Zinuintech completed the registration of a U.S. patent for its recombinant adenovirus-based multivalent influenza vaccine platform.
Zinuintech participated in BioKorea 2021 and introduced its AAV gene therapy platform GT510, aiming to secure clinical trial partners.
An article discussing Zinuintech's innovative technologies and its potential impact on the global biotech industry.
Recognized for its advanced recombinant virus technologies and contributions to the biotech industry.
Zinuintech completed the registration of a U.S. patent for its recombinant adenovirus-based multivalent influenza vaccine platform.
Zinuintech participated in BioKorea 2021 and introduced its AAV gene therapy platform GT510, aiming to secure clinical trial partners.
An article discussing Zinuintech's innovative technologies and its potential impact on the global biotech industry.
Recognized for its advanced recombinant virus technologies and contributions to the biotech industry.